nach oben

Erschienen in:

01.01.2011 | Original Article

Domperidone Treatment for Gastroparesis: Demographic and Pharmacogenetic Characterization of Clinical Efficacy and Side-Effects

verfasst von: Henry P. Parkman, Michael R. Jacobs, Anurag Mishra, Jessica A. Hurdle, Priyanka Sachdeva, John P. Gaughan, Evgeny Krynetskiy

Erschienen in: Digestive Diseases and Sciences | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

Domperidone is a useful alternative to metoclopramide for treatment of gastroparesis due to better tolerability. Effectiveness and side-effects from domperidone may be influenced by patient-related factors including polymorphisms in genes encoding drug-metabolizing enzymes, drug transporters, and domperidone targets.

Aims

The aim of this study was to determine if demographic and pharmacogenetic parameters of patients receiving domperidone are associated with response to treatment or side-effects.

Methods

Patients treated with domperidone for gastroparesis provided saliva samples from which DNA was extracted. Fourteen single-nucleotide polymorphisms (SNPs) in seven candidate genes (ABCB1, CYP2D6, DRD2, KCNE1, KCNE2, KCNH2, KCNQ1) were used for genotyping. SNP microarrays were used to assess single-nucleotide polymorphisms in the ADRA1A, ADRA1B, and ADRA1D loci.

Results

Forty-eight patients treated with domperidone participated in the study. DNA was successfully obtained from each patient. Age was associated with effectiveness of domperidone (p = 0.0088). Genetic polymorphism in KCNH2 was associated with effectiveness of domperidone (p = 0.041). The efficacious dose was associated with polymorphism in ABCB1 gene (p = 0.0277). The side-effects of domperidone were significantly associated with the SNPs in the promoter region of ADRA1D gene.

Conclusions

Genetic characteristics associated with response to domperidone therapy included polymorphisms in the drug transporter gene ABCB1, the potassium channel KCNH2 gene, and α_1D—adrenoceptor ADRA1D gene. Age was associated with a beneficial response to domperidone. If verified in a larger population, this information might be used to help determine which patients with gastroparesis might respond to domperidone and avoid treatment in those who might develop side-effects.

Parkman HP, Hasler WL, Fisher RS. American gastroenterological association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology. 2004;127:1592–1622.CrossRefPubMed

Camilleri M. Clinical practice. Diabetic gastroparesis. N Engl J Med. 2007;356:820–829.CrossRefPubMed

Abell TL, Bernstein RK, Cutts T, et al. Treatment of gastroparesis: a multidisciplinary clinical review. Neurogastroenterol Motil. 2006;18:263–283.CrossRefPubMed

Ahmad N, Keith-Ferris J, Gooden E, Abell T. Making a case for domperidone in the treatment of gastrointestinal motility disorders. Curr Opin Pharmacol. 2006;6:571–576.CrossRefPubMed

Franzese A, Borrelli O, Corrado G, et al. Domperidone is more effective than cisapride in children with diabetic gastroparesis. Aliment Pharmacol Ther. 2002;16:951–957.CrossRefPubMed

Dumitrascu DL, Weinbeck M. Domperidone versus metoclopramide in the treatment of diabetic gastroparesis. Am J Gastroenterol. 2000;95:316–317.CrossRefPubMed

Sadee W, Dai Z. Pharmacogenetics/genomics and personalized medicine. Hum Mol Genet. 2005;14 Spec No. 2:R207–R214.

Ward BA, Morocho A, Kandil A, Galinsky RE, Flockhart DA, Desta Z. Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol. 2004;58:277–287.CrossRefPubMed

Sakaeda T, Nakamura T, Okumura K. MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol Pharm Bull. 2002;25:1391–1400.CrossRefPubMed

10.

Schinkel AH. The roles of P-glycoprotein and MRP1 in the blood-brain and blood-cerebrospinal fluid barriers. Adv Exp Med Biol. 2001;500:365–372.PubMed

11.

Rocha CM, Barbosa MM. QT interval prolongation associated with the oral use of domperidone in an infant. Pediatr Cardiol. 2005;26:720–723.CrossRefPubMed

12.

Pfeufer A, Jalilzadeh S, Perz S, et al. Common variants in myocardial ion channel genes modify the QT interval in the general population: results from the KORA study. Circ Res. 2005;96:693–701.CrossRefPubMed

13.

Tougas G, Eaker EY, Abell TL, et al. Assessment of gastric emptying using a low fat meal: establishment of international control values. Am J Gastroenterol. 2000;95:1456–1462.CrossRefPubMed

14.

Abell TL, Camilleri M, Donohoe K, et al. Consensus recommendations for gastric emptying scintigraphy. A joint report of the Society of Nuclear Medicine and the American Neurogastroenterology and Motility Society. Am J Gastroenterol. 2008;103:753–763.CrossRefPubMed

15.

Maranki JL, Lytes V, Meilahn JE, et al. Predictive factors for clinical improvement with Enterra gastric electric stimulation treatment for refractory gastroparesis. Dig Dis Sci. 2008;53(8):2072–2078.CrossRefPubMed

16.

Krynetskiy E, McDonald O, Dervieux T, Evans W. Molecular diagnostics of thiopurine S-methyltransferase deficiency in cancer drug therapy. In: Wong SHY, Linder MW, Valdes R, eds. Pharmacogenomics and proteomics. Washington, DC: AACC Press; 2006:251–258.

17.

Liu K, Muse SV. PowerMarker: an integrated analysis environment for genetic marker analysis. Bioinformatics. 2005;21:2128–2129.CrossRefPubMed

18.

Uchida H, Mamo DC. Dosing of antipsychotics in schizophrenia across the life-spectrum. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(6):917–920.CrossRefPubMed

19.

Warmke JW, Ganetzky B. A family of potassium channel genes related to eag in Drosophila and mammals. Proc Natl Acad Sci USA. 1994;91(8):3438–3442.CrossRefPubMed

20.

Ackerman MJ, Tester DJ, Jones GS, Will ML, Burrow CR, Curran ME. Ethnic differences in cardiac potassium channel variants: implications for genetic susceptibility to sudden cardiac death and genetic testing for congenital long QT syndrome. Mayo Clin Proc. 2003;78(12):1479–1487.CrossRefPubMed

21.

Sun Z, Milos PM, Thompson JF, et al. Role of a KCNH2 polymorphism (R1047 L) in dofetilide-induced torsades de pointes. J Mol Cell Cardiol. 2004;37(5):1031–1039.CrossRefPubMed

22.

Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res. 2003;58(1):32–45.CrossRefPubMed

23.

Rocha CM, Barbosa MM. QT interval prolongation associated with the oral use of domperidone in an infant. Pediatr Cardiol. 2005;26(5):720–723.CrossRefPubMed

24.

Stork D, Timin EN, Berjukow S, et al. State dependent dissociation of HERG channel inhibitors. Br J Pharmacol. 2007;151(8):1368–1376.CrossRefPubMed

25.

Djeddi D, Kongolo G, Lefaix C, Mounard J, Leke A. Effect of domperidone on QT interval in neonates. J Pediatr. 2008;153(5):663–666.CrossRefPubMed

26.

Gouas L, Nicaud V, Chaouch S, et al. Confirmation of associations between ion channel gene SNPs and QTc interval duration in healthy subjects. Eur J Hum Genet. 2007;15:974–979.CrossRefPubMed

27.

Ward BA, Morocho A, Kandi A, Galinsky RE, Flockhart DA, Desta Z. Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol. 2004;58:277–287.CrossRefPubMed

28.

Simard C, Michaud V, Gibbs B, et al. Identification of the cytochrome P450 enzymes involved in the metabolism of domperidone. Xenobiotica. 2004;34:1013–1023.CrossRefPubMed

29.

Perera MA. The missing linkage: what pharmacogenetic associations are left to find in CYP3A? Expert Opin Drug Metab Toxicol. 2010;6:17–28.CrossRefPubMed

30.

Fung KL, Gottesman MM. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta. 2009;1794:860–871.PubMed

31.

Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J. Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003;46(9):1716–1725.CrossRefPubMed

32.

Gow JM, Hodges LM, Chinn LW, Kroetz DL. Substrate-dependent effects of human ABCB1 coding polymorphisms. J Pharmacol Exp Ther. 2008;325:435–442.CrossRefPubMed

33.

Kimchi-Sarfaty C, Gribar JJ, Gottesman MM. Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol Pharmacol. 2002;62:1–6.CrossRefPubMed

34.

McBride BF, Yang T, Roden DM. Influence of the G2677T/C3435T haplotype of MDR1 on P-glycoprotein trafficking and ibutilide-induced block of HERG. Pharmacogenomics J. 2009;9:194–201.CrossRefPubMed

35.

Keiser MJ, Setola V, Irwin JJ, et al. Predicting new molecular targets for known drugs. Nature. 2009;462(7270):175–181.CrossRefPubMed

36.

Clark DA, Arranz MJ, Mata I, Lopez-Ilundain J, Perez-Nievas F, Kerwin RW. Polymorphisms in the promoter region of the alpha1A-adrenoceptor gene are associated with schizophrenia/schizoaffective disorder in a Spanish isolate population. Biol Psychiatry. 2005;58(6):435–439.CrossRefPubMed

37.

Nonen S, Okamoto H, Fujio Y, et al. Polymorphisms of norepinephrine transporter and adrenergic receptor alpha1D are associated with the response to beta-blockers in dilated cardiomyopathy. Pharmacogenomics J. 2008;8(1):78–84.CrossRefPubMed

38.

Ma J, Rayner CK, Jones KL, Horowitz M. Diabetic gastroparesis: diagnosis and management. Drugs. 2009;69:971–986.CrossRefPubMed

39.

Lacy BE, Weiser K. Gastrointestinal motility disorders: an update. Dig Dis. 2006;24:228–242.CrossRefPubMed

40.

Silvers D, Kipnes M, Broadstone V, et al. Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. DOM-USA-5 study group. Clin Ther. 1998;20:438–453.CrossRefPubMed

41.

Sawant P, Das HS, Desai N, et al. Comparative evaluation of the efficacy and tolerability of itopride hydrochloride and domperidone in patients with non-ulcer dyspepsia. J Assoc Physicians India. 2004;52:626–628.PubMed

42.

Hegar B, Alatas S, Advani N, et al. Domperidone versus cisapride in the treatment of infant regurgitation and increased acid gastro-oesophageal reflux: a pilot study. Acta Paediatr. 2009;98:750–755.CrossRefPubMed

43.

Gunlemez A, Babaoglu A, Arisoy AE, et al. Effect of domperidone on the QTc interval in premature infants. J Perinatol. 2010;30:50–53.CrossRefPubMed

44.

Rocha CM, Barbosa MM. QT interval prolongation associated with the oral use of domperidone in an infant. Pediatr Cardiol. 2005;26:720–723.CrossRefPubMed

Titel: Domperidone Treatment for Gastroparesis: Demographic and Pharmacogenetic Characterization of Clinical Efficacy and Side-Effects
verfasst von: Henry P. Parkman
Michael R. Jacobs
Anurag Mishra
Jessica A. Hurdle
Priyanka Sachdeva
John P. Gaughan
Evgeny Krynetskiy
Publikationsdatum: 01.01.2011
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 1/2011
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-010-1472-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Aims

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2011

Fracture-Associated Hospitalizations in Patients with Inflammatory Bowel Disease

Non-cirrhotic Intrahepatic Portal Hypertension: Associated Gut Diseases and Prognostic Factors

Erratum to: Expression and Prognostic Value of ZNRD1 in Esophageal Squamous Cell Carcinoma

Capsule Endoscopy in the Diagnosis of Suspected Small Bowel Involvement with Crohn’s Disease

Conversion to Combined Mycophenolate Mofetil and Low-Dose Calcineurin Inhibitor Therapy for Renal Dysfunction in Liver Transplant Patients: Never Too Late?